321 related articles for article (PubMed ID: 37279256)
21. Immunogenomic profiles associated with response to life-prolonging agents in prostate cancer.
Conteduca V; Brighi N; Schepisi G; De Giorgi U
Br J Cancer; 2023 Oct; 129(7):1050-1060. PubMed ID: 37443349
[TBL] [Abstract][Full Text] [Related]
22. Beyond the Androgen Receptor: The Sequence, the Mutants, and New Avengers in the Treatment of Castrate-Resistant Metastatic Prostate Cancer.
Westaby D; Viscuse PV; Ravilla R; de la Maza MLDF; Hahn A; Sharp A; de Bono J; Aparicio A; Fleming MT
Am Soc Clin Oncol Educ Book; 2021 Jun; 41():e190-e202. PubMed ID: 34061561
[TBL] [Abstract][Full Text] [Related]
23. Clinical and molecular features of treatment-related neuroendocrine prostate cancer.
Akamatsu S; Inoue T; Ogawa O; Gleave ME
Int J Urol; 2018 Apr; 25(4):345-351. PubMed ID: 29396873
[TBL] [Abstract][Full Text] [Related]
24. BMX-Mediated Regulation of Multiple Tyrosine Kinases Contributes to Castration Resistance in Prostate Cancer.
Chen S; Cai C; Sowalsky AG; Ye H; Ma F; Yuan X; Simon NI; Gray NS; Balk SP
Cancer Res; 2018 Sep; 78(18):5203-5215. PubMed ID: 30012673
[TBL] [Abstract][Full Text] [Related]
25. Biological Evolution of Castration-resistant Prostate Cancer.
Davies A; Conteduca V; Zoubeidi A; Beltran H
Eur Urol Focus; 2019 Mar; 5(2):147-154. PubMed ID: 30772358
[TBL] [Abstract][Full Text] [Related]
26. Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer.
Ferrari N; Granata I; Capaia M; Piccirillo M; Guarracino MR; Venè R; Brizzolara A; Petretto A; Inglese E; Morini M; Astigiano S; Amaro AA; Boccardo F; Balbi C; Barboro P
Cell Commun Signal; 2017 Dec; 15(1):51. PubMed ID: 29216878
[TBL] [Abstract][Full Text] [Related]
27. New Opportunities for Targeting the Androgen Receptor in Prostate Cancer.
Centenera MM; Selth LA; Ebrahimie E; Butler LM; Tilley WD
Cold Spring Harb Perspect Med; 2018 Dec; 8(12):. PubMed ID: 29530945
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of Systemic Treatment in Prostate Cancer Patients With Visceral Metastasis: A Systematic Review, Meta-analysis, and Network Meta-analysis.
Yanagisawa T; Rajwa P; Kawada T; Mori K; Fukuokaya W; Petrov P; Quhal F; Laukhtina E; von Deimling M; Bianchi A; Majdoub M; Pradere B; Kramer G; Kimura T; Shariat SF
J Urol; 2023 Sep; 210(3):416-429. PubMed ID: 37339479
[TBL] [Abstract][Full Text] [Related]
29. A rare castration-resistant progenitor cell population is highly enriched in Pten-null prostate tumours.
Sackmann Sala L; Boutillon F; Menara G; De Goyon-Pélard A; Leprévost M; Codzamanian J; Lister N; Pencik J; Clark A; Cagnard N; Bole-Feysot C; Moriggl R; Risbridger GP; Taylor RA; Kenner L; Guidotti JE; Goffin V
J Pathol; 2017 Sep; 243(1):51-64. PubMed ID: 28603917
[TBL] [Abstract][Full Text] [Related]
30. The Role of Epigenetic Change in Therapy-Induced Neuroendocrine Prostate Cancer Lineage Plasticity.
Storck WK; May AM; Westbrook TC; Duan Z; Morrissey C; Yates JA; Alumkal JJ
Front Endocrinol (Lausanne); 2022; 13():926585. PubMed ID: 35909568
[TBL] [Abstract][Full Text] [Related]
31. [ASC-J9 for castration-resistant prostate cancer].
Yamashita S; Arai Y
Nihon Rinsho; 2014 Dec; 72(12):2126-9. PubMed ID: 25518345
[TBL] [Abstract][Full Text] [Related]
32. Basic Science and Molecular Genetics of Prostate Cancer Aggressiveness.
Schiewer MJ; Knudsen KE
Urol Clin North Am; 2021 Aug; 48(3):339-347. PubMed ID: 34210489
[TBL] [Abstract][Full Text] [Related]
33. Molecular model for neuroendocrine prostate cancer progression.
Chen R; Dong X; Gleave M
BJU Int; 2018 Oct; 122(4):560-570. PubMed ID: 29569310
[TBL] [Abstract][Full Text] [Related]
34. Targeting the androgen receptor signaling pathway in advanced prostate cancer.
Chung C; Abboud K
Am J Health Syst Pharm; 2022 Jul; 79(15):1224-1235. PubMed ID: 35390118
[TBL] [Abstract][Full Text] [Related]
35. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
Martin SK; Kyprianou N
Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
[TBL] [Abstract][Full Text] [Related]
36. Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer.
Chen X; Shao Y; Wei W; Zhu S; Li Y; Chen Y; Li H; Tian H; Sun G; Niu Y; Shang Z
Cell Death Dis; 2022 Nov; 13(11):927. PubMed ID: 36335093
[TBL] [Abstract][Full Text] [Related]
37. MYBL2 disrupts the Hippo-YAP pathway and confers castration resistance and metastatic potential in prostate cancer.
Li Q; Wang M; Hu Y; Zhao E; Li J; Ren L; Wang M; Xu Y; Liang Q; Zhang D; Lai Y; Liu S; Peng X; Zhu C; Ye L
Theranostics; 2021; 11(12):5794-5812. PubMed ID: 33897882
[No Abstract] [Full Text] [Related]
38. ROLE OF ANDROGEN RECEPTOR-TARGETED AGENTS IN LOCALIZED PROSTATE CANCER.
Murgić J; Fröbe A; Challapalli A; Bahl A
Acta Clin Croat; 2022 Oct; 61(Suppl 3):51-56. PubMed ID: 36938555
[TBL] [Abstract][Full Text] [Related]
39. Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer.
Bastos DA; Dzik C; Rathkopf D; Scher HI
Oncology (Williston Park); 2014 Aug; 28(8):693-9. PubMed ID: 25140626
[TBL] [Abstract][Full Text] [Related]
40. Downregulation of
Russo JW; Gao C; Bhasin SS; Voznesensky OS; Calagua C; Arai S; Nelson PS; Montgomery B; Mostaghel EA; Corey E; Taplin ME; Ye H; Bhasin M; Balk SP
Cancer Res; 2018 Nov; 78(22):6354-6362. PubMed ID: 30242112
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]